Your browser doesn't support javascript.
loading
Paediatric aortic valve replacement using decellularized allografts: a multicentre update following 143 implantations and five-year mean follow-up.
Horke, Alexander; Bobylev, Dmitry; Avsar, Murat; Cvitkovic, Tomislav; Meyns, Bart; Rega, Filip; Hazekamp, Mark; Cesnjevar, Robert; Schmiady, Martin; Staebler, Brigitte; Dewald, Oliver; Ciubotaru, Anatol; Michel-Behnke, Ina; Zimpfer, Daniel; Jashari, Ramadan; Boethig, Dietmar; Cebotari, Serghei; Beerbaum, Philipp; Tudorache, Igor; Sarikouch, Samir.
Afiliação
  • Horke A; Department for Cardiothoracic, Transplant, and Vascular Surgery, Hannover Medical School, Hannover, Germany.
  • Bobylev D; Department for Cardiothoracic, Transplant, and Vascular Surgery, Hannover Medical School, Hannover, Germany.
  • Avsar M; Department for Cardiothoracic, Transplant, and Vascular Surgery, Hannover Medical School, Hannover, Germany.
  • Cvitkovic T; Department for Cardiothoracic, Transplant, and Vascular Surgery, Hannover Medical School, Hannover, Germany.
  • Meyns B; Department of Cardiac Surgery, Katholieke Universiteit Leuven, Belgium.
  • Rega F; Department of Cardiac Surgery, Katholieke Universiteit Leuven, Belgium.
  • Hazekamp M; Department of Cardiothoracic Surgery, Leiden University Medical Center, Netherlands.
  • Cesnjevar R; Division of Congenital Cardiovascular Surgery, University Children's Hospital, Zurich, Switzerland.
  • Schmiady M; Division of Congenital Cardiovascular Surgery, University Children's Hospital, Zurich, Switzerland.
  • Staebler B; Department of Cardiac Surgery, Sana Herzchirurgie, Stuttgart, Germany.
  • Dewald O; Division of Pediatric Cardiac Surgery, University of Erlangen, Erlangen, Germany.
  • Ciubotaru A; Cardiac Surgery Center, State Medical and Pharmaceutical University, Chisinau, Moldova.
  • Michel-Behnke I; Department of Pediatric Cardiology, Medical University of Vienna, Austria.
  • Zimpfer D; Department of Cardiac Surgery, Medical University of Vienna, Austria.
  • Jashari R; European Homograft Bank, Clinique Saint-Jean, Brussels, Belgium.
  • Boethig D; Department for Cardiothoracic, Transplant, and Vascular Surgery, Hannover Medical School, Hannover, Germany.
  • Cebotari S; Department for Pediatric Cardiology and Intensive Care, Hannover Medical School, Germany.
  • Beerbaum P; Department of Cardiac Surgery, Institute for Cardiac Surgery and Interventional Cardiology, Luxembourg, Luxembourg.
  • Tudorache I; Department for Pediatric Cardiology and Intensive Care, Hannover Medical School, Germany.
  • Sarikouch S; Department for Cardiothoracic, Transplant, and Vascular Surgery, Hannover Medical School, Hannover, Germany.
Eur J Cardiothorac Surg ; 65(4)2024 Mar 29.
Article em En | MEDLINE | ID: mdl-38532286
ABSTRACT

OBJECTIVES:

Decellularized aortic homografts (DAH) were introduced in 2008 as a further option for paediatric aortic valve replacement (AVR).

METHODS:

Prospective, multicentre follow-up of all paediatric patients receiving DAH for AVR in 8 European centres.

RESULTS:

A total of 143 DAH were implanted between February 2008 and February 2023 in 137 children (106 male, 74%) with a median age of 10.8 years (interquartile range 6.6-14.6). Eighty-four (59%) had undergone previous cardiac operations and 24 (17%) had undergone previous AVR. The median implanted DAH diameter was 21 mm (interquartile range 19-23). The median operation duration was 348 min (227-439) with a median cardiopulmonary bypass time of 212 min (171-257) and a median cross-clamp time of 135 min (113-164). After a median follow-up of 5.3 years (3.3-7.2, max. 15.2 years), the primary efficacy end-points peak gradient (median 14 mmHg, 9-28) and regurgitation (median 0.5, interquartile range 0-1, grade 0-3) showed good results but an increase over time. Freedom from death/explantation/endocarditis/bleeding/thromboembolism at 5 years were 97.8 ± 1.2/88.7 ± 3.3/99.1 ± 0.9/100 and 99.2 ± 0.8%, respectively. Freedom from death/explantation/endocarditis/bleeding/thromboembolism at 10 years were 96.3 ± 1.9/67.1 ± 8.0/93.6 ± 3.9/98.6 ± 1.4 and 86.9 ± 11.6%, respectively. In total, 21 DAH were explanted. Seven were replaced by a mechanical AVR, 1 Ross operation was performed and a re-do DAH was implanted in 13 patients with no redo mortality. The calculated expected adverse events were lower for DAH compared to cryopreserved homograft patients (mean age 8.4 years), and in the same range as for Ross patients (9.2 years) and mechanical AVR (13.0 years).

CONCLUSIONS:

This large-scale prospective analysis demonstrates excellent mid-term survival using DAH with adverse event rates comparable to paediatric Ross procedures.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tromboembolia / Próteses Valvulares Cardíacas / Implante de Prótese de Valva Cardíaca / Endocardite Limite: Adolescent / Child / Female / Humans / Male Idioma: En Revista: Eur J Cardiothorac Surg Assunto da revista: CARDIOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tromboembolia / Próteses Valvulares Cardíacas / Implante de Prótese de Valva Cardíaca / Endocardite Limite: Adolescent / Child / Female / Humans / Male Idioma: En Revista: Eur J Cardiothorac Surg Assunto da revista: CARDIOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Alemanha